GSK's Key Drugs to Drive Sales in a Sluggish Second Half – Zacks Investment Research

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
Don't Know Your Password?

New to Zacks? Get started here.
Don't Know Your Password?

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OK Cancel
Image: Bigstock
Zacks Equity Research October 05, 2022
GSK PFE VIR HLN
Trades from $1
You follow Analyst Blog – edit
You follow Zacks Equity Research – edit


GSK’s (GSK Free Report) relatively newer specialty products like Nucala (severe eosinophilic asthma), Bexsero (meningitis vaccine), Shingrix (shingles vaccines), Trelegy Ellipta (three medicines in a single inhaler to treat COPD) and Juluca (dolutegravir+ rilpivirine once-daily, single pill for HIV) have witnessed considerable success and have become key drivers of top-line growth. Sales of these products are making up for a decline in Established Pharmaceuticals due to generic erosion.  GSK expects its new medicines and vaccines (approved between 2017 and 2021) to contribute around 60% of the new GSK’s (after CHC demerger) sales growth for the period 2022-2026.
GSK has made significant progress in its pipeline. Promising candidates in late-stage development include momelotinib (myelofibrosis), otilimab (rheumatoid arthritis), gepotidacin (uncomplicated urinary tract infection and urogenital gonorrhoea), bepirovirsen (chronic hepatitis B), depemokimab (severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome and chronic rhinosinusitis with nasal polyps) and RSV vaccines for older adults.
Key new drug approvals in the past couple of years were Rukobia/fostemsavir for heavily pre-treated HIV, Blenrep/belantamab mafatotin for fourth-line multiple myeloma; Cabenuva, a long-acting injectable HIV treatment; Jemperli (dostarlimab) for second-line endometrial cancer and mismatch repair-deficient (dMMR) recurrent or advanced solid tumors and Apretude, a long-acting injectable form of cabotegravir drug for the prevention of HIV infection, also called pre-exposure prophylaxis or PrEP. These new products should contribute meaningfully to revenue growth in coming years.
In 2020/2021, GSK established multiple partnerships to develop COVID-19 solutions, including with Sanofi, Medicago, SK Biosciences to make adjuvanted COVID-19 vaccine and with Vir Biotechnology (VIR Free Report) for therapeutic antibody treatments like Xevudy (sotrovimab). GSK/Vir Biotechnology’s Xevudy was authorized in the United States in May 2021 and Europe in December 2021. Xevudy generated sales of almost £1.78 billion for GSK in the first half of 2022. GSK is also increasing investment in the mRNA platform.
Several new drug/line extension approvals are expected in the near future, which should boost sales. GSK plans to launch more than 20 new products/line extensions by 2026, with more than 10 having blockbuster potential.
In July, GSK completed the spin-off of its Consumer Healthcare segment into a new standalone company called Haleon (HLN Free Report) . GSK’’s Consumer Healthcare segment was a joint venture with Pfizer (PFE Free Report) formed by the merger of their respective Consumer Healthcare units in 2019. GSK shareholders own 54.5% stake in Haleon, while 6% is held by GSK. Pfizer holds a 32% stake in Haleon and plans to sell this stake soon. The spin-off of the Consumer unit has allowed GSK to focus on its drug development.
GSK’s vaccine sales recovered in 2022 after being hurt by COVID-related disruptions in several marketsin 2021.In 2022, the company expects vaccine sales to grow at low to mid-teens percentage points (previously low-teens percentage points), excluding pandemic solutions.
For its shingles vaccine, Shingrix, GSK expects double-digit growth to be driven by strong demand in existing markets and geographical expansion.
GSK has its share of problems. While GSK’s first-half performance was better than expected and ahead of the full-year guidance, it expects lower reported growth in the second half. Compared with the first half of the year, GSK expects to record slightly lower sales in the second half of 2022 due to some channel stocking in the United States during the first half of 2022. With regard to its COVID-19 solutions, GSK expects sales to be substantially lower in the second half. GSK said that the majority of expected COVID-19 solutions sales for 2022 were achieved in the first half of 2022.
Generic competition for key drug, Advair is hampering sales of GSK’s respiratory products, which we believe may not be compensated by new respiratory drugs. Competitive pressure on HIV drugs has risen.
Nonetheless, strong sales of specialty medicines, regular pipeline success and accretive M&A deals should keep the stock afloat, going forward.
GSK PLC Sponsored ADR (GSK) – free report >>
Pfizer Inc. (PFE) – free report >>
Vir Biotechnology, Inc. (VIR) – free report >>
Haleon PLC Sponsored ADR (HLN) – free report >>
Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next 30-90 days.
Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better. See our report’s 7 new picks today, absolutely FREE.
Privacy Policy No cost, no obligation to buy anything ever.
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor’s Business Daily, Inc.; and Morningstar, Inc.
Copyright 2022 Zacks Investment Research 10 S Riverside Plaza Suite #1600 Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.51% per year. These returns cover a period from January 1, 1988 through September 12, 2022. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

source

Add a Comment

Your email address will not be published. Required fields are marked *